Finnish medical technology startup, a SPARK Finland alumni Epiheart Oy, has raised more than 600.000 euro in a crowdfunding seed round for development of their Cardiac Micrograft Therapy™ – a new method to treat cardiac damage caused by oxygen deficiency. Funding round was organized by Invesdor Oy.
The treatment method has been researched and developed over a long period of time through academic research, especially at the University of Helsinki and the Helsinki University Hospital HUS. The results gained from the research and the first patients, as well as the results of the preceding trials, have been promising. The treatment is administered in connection to surgery and is based on the patient’s own cells. It has good prospects to become the first cellular or tissue therapy that is approved for extensive clinical use. Treatment can be implemented by using the medical equipment designed by EpiHeart for use in connection to cardiac surgery and optimized to be simple to use, which enables a quick entrance into the market.
SPARK Finland congratulates Kai Kronström, whole EpiHeart team, and Invesdor for a great success in funding round!